Sanjeev Valentine’s Post

Big Moves in Cardiovascular Tech: Acquisitions Shake Up the Industry The cardiovascular technology landscape is experiencing a wave of consolidation and innovation. Here's a look at some recent acquisitions that are shaping the future of heart health: #Johnson & Johnson made a major splash with its $13.1 billion acquisition of #Shockwave Medical. Shockwave's intravascular lithoplasty (IVL) technology offers a minimally invasive approach to treating coronary artery disease. This deal strengthens J&J's position in a rapidly growing market segment. #AstraZeneca bolstered its cardiovascular portfolio with the $1.8 billion acquisition of #CinCor. This move expands their presence in the treatment of resistant hypertension, a condition where blood pressure remains high despite medication. #Nordson Corporation entered the cardiovascular space by acquiring #Atrion Corporation. Atrion specializes in medical infusion and niche #cardiovascular solutions, broadening Nordson's reach in the medical technology sector. Becton Dickinson (#BD) recently announced a $4.2 billion acquisition of #Edwards #Lifesciences' Critical Care product group. This strategic move bolsters BD's presence in advanced patient monitoring technologies, particularly AI-driven solutions. The combined entity is expected to leverage BD's global reach and Edwards' expertise to create new opportunities in data analysis and #innovation for critical care.

After their divesture, Edwards Lifesciences is on an acquisition spree to double down on the structural heart market by purchasing Genesis Medtech's JC Medical business to boost its transcatheter aortic valve replacement (TAVR) technology. This acquisition includes intellectual property and commercial rights for the innovative J-Valve system, designed to treat severe aortic regurgitation. Alongside this deal, Edwards has invested $25 million in Genesis to fuel further market and product development. This move is part of a broader strategy by Edwards to solidify its grip on the cardiac treatment landscape. Just last month, Edwards shelled out $1.2 billion to acquire JenaValve Technology and Endotronix, both pioneers in heart valve and heart failure technologies. Also on the docket was a $300 million purchase of Innovalve Bio Medical. Why the buying spree amid lower-than-expected TAVR volumes? It appears that Edwards is positioning itself for a strong competitive future, seeing potential in diversified, breakthrough tech to address unmet medical needs. The J-Valve system, which earned a breakthrough device designation from the FDA in August 2023, is another feather in Edwards' cap. Impressively, JC Medical completed enrollment for its early feasibility study in the U.S. in February and has entered the pivotal trial phase. This is a promising stride towards addressing aortic regurgitation and adding significant value to Edwards' already robust portfolio. What are your thoughts on Edwards Lifesciences' latest move? Let's spark a discussion on the evolving landscape of cardiac treatments and acquisitions. #Medtech #Cardiology #M&A

MedTech M&A activity has been heating up in 2024! 📈 H1 2024 saw several significant deals in the MedTech industry, to name a few: GE HealthCare acquired IMACTIS for $245M to boost image-guided interventions. Medtronic strengthened its diabetes portfolio with a $738M purchase of EOFlow. Stryker invested $1B in Collagen Matrix Inc. to advance in surgical implants. Teleflex bought Palette Life Sciences for $600M, expanding in minimally invasive care. Smith+Nephew partnered with Navbit to enhance its orthopedic offerings. 🏥These moves highlight the industry's shift towards innovation, digital health, and patient-centric solutions! It’s encouraging to see such strategic activity driving growth and pushing boundaries, especially as companies adapt to evolving healthcare needs and embrace cutting-edge technologies. https://lnkd.in/gvQTeaEg #MedTech #HealthcareInnovation #DigitalHealth

Johnson & Johnson look to have their sights set on another major acquisition in Shockwave Medical. WSJ cited people familiar with the matter. They said the acquisition talks, if successful, could result in a finalized deal in the coming weeks. Another suitor could also seek a merger with Santa Clara, California–based Shockwave. Founded in 2009, Shockwave Medical has intravascular lithotripsy technology that uses sonic pressure waves to treat people with calcified arterial plaque. 2023 saw them bring in $489.7 million in revenue and their shares are trading 10 times higher than they were when the company initially went public in 2019. This isn’t the first time that Shockwave has been the subject of reports of a potential acquisition. Media reports last year mentioned Johnson & Johnson, Medtronic and Boston Scientific as potential suitors. #vidanews #medtech #medicaldevices #acquisition #cardiovascular

🎉 ONWARD Medical raises €20 Million in context of the approval and launch of first products for people with spinal cord injury 🎉 The #medtech company envisions using the proceeds to ▸ Fund R&D activities, including continued product development and regulatory approval of the investigational ARC-EX System to restore hand and arm function and the investigational ARC-IM System for improved blood pressure regulation after spinal cord injury; ▸ Establish a commercial organization in preparation for expected US launch of the ARC-EX System second half of this year; ▸ Build quality, operations, and other infrastructure capabilities. Read more 👇 #VDTech #SwissTech #startupfunding

Major medtech M&A news this morning: Johnson & Johnson has agreed to acquire Shockwave Medical for approximately $13.1 billion. The deal values Shockwave at $335 per share. Both companies’ boards have approved the transaction, and J&J expects the deal to close in mid-2024. Shockwave makes medical devices that break up calcium deposits in coronary arteries using sound pressure waves, a technique called intravascular lithotripsy. The company forecast a sales range of from $910 million to $930 million for 2024, and had $990.6 million in cash or cash equivalents as of Dec. 31. J&J has recently had a run of medtech M&A: The company purchased Laminar for $400 million in November and Abiomed for $16.6 billion in 2022.

#Endoscopy_Devices Market Share Expected Huge Growth during 2022-2030 https://bit.ly/3NF2a7A The #Endoscopy #Devices market 2022 research #report gives emerging industry #data, global #segments and regional outlook. This report covers up all details such as #size, share, #value, #growth, restraints, and #opportunities for the year 2022 to 2030. The report generated using various #analysis tools like porter’s five forces #model, #market #attractiveness and value chain. Olympus Corporation , KARL STORZ Stryker , Boston Scientific Johnson & Johnson , FUJIFILM Holdings Corporation , Medtronic. Hoya , Nipro Corporation , Smith & Nephew, Inc. Richard Wolf GmbH , CONMED Corporation , Intuitive, Cook Medical , Ambu A/S CapsoVision, Inc. , Fortimedix Surgical B.V. BKK B. Braun Melsungen AG Medi-Globe , THE COOPER COMPANIES GLOBAL HOLDINGS LP, Dantschke Medizintechnik GmbH & Co. KG , LABORIE MEDICAL TECHNOLOGIES EUROPE Teleflex , Cantel Medical #researchreport #medicalequipment #endoscopydevices #healthcareindustry

Edwards Lifesciences is on a growth trajectory, investing $1.2 billion to acquire two innovative cardiac device companies. This strategic move expands their structural heart portfolio and addresses critical areas in cardiac care. The acquisitions include JenaValve Technology, which is pioneering a treatment for aortic regurgitation, and Endotronix, which offers an implantable pulmonary artery pressure sensor for heart failure. This announcement comes as Edwards reported a slowdown in their core TAVR business for Q2, which has affected their share prices. Despite this, the company remains optimistic about the future. They believe these new investments will drive long-term growth and enhance their presence in niche markets of aortic disease and heart failure treatment. Moreover, Edwards’ TMTT (transcatheter mitral and tricuspid therapies) segment has shown remarkable growth, with a 75% increase in sales year-over-year. This progress highlights their ability to innovate and adapt in a rapidly evolving medical landscape. These acquisitions are a testament to Edwards’ commitment to advancing healthcare solutions and addressing unmet needs in cardiac care. https://lnkd.in/dzXu8XVv #CardiacInnovation #MedTech #HealthcareLeadership

🚀 Edwards keeps M&A streak going with JC Medical Acquisition! Edwards Lifesciences has just made a very interesting move by acquiring JC Medical, Inc. and its innovative J-Valve system. This acquisition includes all intellectual property and commercial rights related to J-Valve, a pioneering transcatheter aortic valve replacement (TAVR) system. This strategic decision continues Edwards' trend of key acquisitions in the MedTech space, including recent acquisitions of JenaValve, Endotronics and Innovalve Bio Medical. The J-Valve system comes with an FDA breakthrough device designation, showing its massive potential for treating severe native aortic regurgitation (AR) and AR-dominant mixed aortic valve disease. Known for its minimally invasive, transfemoral procedure, J-Valve eliminates the need for open-heart surgeries. This advancement could be a game-changer for those affected by these conditions, which are often underserved by current treatments in the US. With Edwards' backing, including an equity investment of $25 million in Genesis MedTech, the future looks bright for J-Valve's global impact. What do you think this means for the future of TAVR systems and heart valve treatments in general? Share your thoughts below or visit www.rinconsearchgroup.com to learn more. #MedTech #HealthcareInnovation #JValve

Wow, that's an impressive roll-up strategy from J&J: buy Abiomed for $16.6bn then pick up its CVC portfolio company, medical device maker Shockwave Medical, for $13.1bn. https://lnkd.in/edpGuzYM Abiomed invested $15m in Shockwave in 2018 before its IPO at a market cap of less than $1bn, according to Thierry's report https://lnkd.in/eeNWphrN Still, almost-$30bn is a good chunk of change having reaped some profits from flipping out its consumer group, Kenvue. But the buy-and-build strategy and more creative use of the balance sheet will be a hot topic in the health sector for many more groups